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Abstract
Background and aims Patients with bilobular colorectal
liver metastases (CRLM) experience poor prognosis,
especially when curative resection cannot be achieved.
However, resectability in these patients is often limited by
low future remnant liver volume (FRLV). The latter can be
enhanced by a two-stage liver resection, using portal vein
ligation to induce liver hypertrophy. The aim of this
prospective pilot study was to evaluate safety, secondary
resectability, and time to recurrence of two-stage hepatec-
tomy with portal vein ligation (PVL) and complete surgical
clearance of the FRLV in patients with bilobular CRLM.
Materials and methods Out of 24 patients (63±8.26 years)
with extended bilobularC R L M( m e t a c h r o n o u sn=10,
synchronous n=14), 18 received preoperative 5-FU-based
chemotherapy combined with oxaliplatin or irinotecan.
Staging included thoracoabdominal computed tomography
and
18F-fluorodeoxyglucose-positron emission tomography
scans. First-stage procedure consisted of PVL, resection of
all CRLM in the FRLV, and radiofrequency ablation (RFA)
of CRLM situated near the future resection plane.
Results During first-stage procedure, 7× RFA, 4× non-
anatomical resections, and 4× bisegmentectomies were
performed additionally to PVL. FRLV/body-weight ratio
increased from 0.4% to 0.6% within 55 days (median) after
PVL. Second-stage hepatectomy was performed in 19
patients without tumor progression. R0 resection was
possible in 14 patients. During a median follow-up of
17 months, intrahepatic recurrence occurred in two, and
extrahepatic recurrence in nine out of 14 patients.
Conclusion Two-stage hepatectomy with PVL and com-
plete surgical clearance of FRLV is safe even after
intensified systemic chemotherapy resulting in a curative
resection rate of 58.3% (73.7% of re-explored cases).
Keywords Bilobularcolorectallivermetastases.Two-stage
hepatectomy.Portalveinligation.Insufficientfuture
remnantlivervolume.Liver hypertrophy
Introduction
Liver resection is the only potentially curative treatment
option of colorectal cancer metastases (CRLM). It has
become the standard of care even in patients with multiple
metastases, resulting in 5-year survival rates of 37–50% in
specialized centers [1, 2]. However, in case of bilobular
involvement, patients experience a poorer outcome, with 5-
year survival rates of only 20% [3]. As this still is beneficial
when compared to intensive systemic chemotherapy alone
[4], surgical approaches are recommended even in this
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Göttingen, Germanychallenging subgroup of patients, provided that curative
resection appears achievable. Unfortunately, 70–80% of
patients presenting with multiple and/or bilobular CRLM
are not resectable at the time of diagnosis [5]. In patients
without extrahepatic spread, unresectability is mainly due
to an insufficient amount of future remnant liver volume
(FRLV) [6], which, in the absence of chronic liver disease,
can be estimated as less than 30% of the initial total liver
volume [7] or a FRLV to body weight ratio of <0.5% [8]. It
has been demonstrated that secondary resectability in these
cases can be achieved by either preoperative chemotherapy,
portal vein occlusion, or both. While preoperative chemo-
therapy leads to an effective downsizing of CRLM [9],
portal vein occlusion, performed as surgical ligation (PVL)
or as interventional embolization (PVE), induces significant
hypertrophy of the FRLV [10]. Portal vein occlusion
thereby allows extended two-stage hepatectomy without
transient liver failure [11]. In our experience, neither
preoperative chemotherapy nor the number of metastases
influence tumor-related overall survival when curative
resection can be achieved (Fig. 1a,b). Additionally, Shaw
et al. [12] reported 5-year survival rates of 44% after
second hepatectomy for recurrent CRLM. Adam et al. [13]
even described a 5-year survival rate of 32% after third
hepatectomy. Although these data are encouraging and
seem to justify aggressive multidisciplinary approaches,
there is still no consensus on what the optimal oncological
strategy should be.
The present prospective pilot study on 24 patients with
bilobular CRLM describes an intensive multimodal treat-
ment concept, including preoperative chemotherapy and
two-stage hepatectomy with portal vein ligation (PVL) and
complete surgical clearance of the FRLV. The paper focuses
on feasibility, safety, and surgical and preliminary onco-
logical outcome.
Materials and methods
All interventions were performed according to established
surgical procedures and actual guidelines for the treatment
of colorectal and hepatobiliary diseases by the German
Society of Surgeons.
Between April 2005 and November 2007, 24 patients
with a mean age of 63±8.26 (range 42–76) years and
presenting with bilobular CRLM were selected for a two-
stage liver resection with PVL. All data were collected
prospectively. The characteristics of the 24 patients are
summarized in Table 1. Seven female and 17 male patients
were included in the study. Primary tumor location was
colon and rectum in 12 patients each. One patient received
neoadjuvant radiochemotherapy before rectal resection, and
eight patients were treated by chemotherapy in an adjuvant
setting after resection of the primary tumor. CRLM were
synchronous in 14 patients (time between primary cancer
resection and diagnosis of CRLM <3 month) and meta-
chronous in ten patients, with a median disease-free
survival between primary tumor resection and diagnosis
of CRLM of 20 (range, 8–183) months.
Three patients had been included in our study because
of intrahepatic recurrence. Two of these had undergone
previous curative non-anatomic liver resection. The third
patient had been treated by systemic chemotherapy with
5-fuorouracil, folinic acid, and oxaliplatin for synchro-
nous CRLM, resulting in complete remission based on
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria [14] but presented with intrahepatic recurrence
22 months later.
Fig. 1 a Kaplan–Meier-plot on overall survival after salvage resection
of colorectal liver metastases with curative intent (n=106). Patients
were stratified based on number of metastases but irrespective of
preoperative and adjuvant treatment (University Medical Center
Goettingen, Department for General and Visceral Surgery 2001–
2007). b Kaplan–Meier plot on overall survival after salvage resection
of colorectal liver metastases with curative intent (n=106). Patients
were stratified according to preoperative treatment (chemotherapy
versus no chemotherapy) irrespective of number of metastases,
resection type, or adjuvant treatment (University Medical Center
Goettingen, Department of General and Visceral Surgery 2001–2007)
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therapy with oxaliplatin or irinotecan; six (33%) of them
were treated additionally with the vascular endothelial
growth factor antibody, bevacizumab. According to RECIST
criteria, eight of the 18 patients (44.4%) showed stable
disease or even partial response, while in ten patients
(55.6%), progressive disease confined to the liver was
observed (Table 2). However, in the latter, resectability
had never been assessed by an experienced hepatobiliary
surgeon before, but at restaging prior to our study, curative
resection seemed to be achievable despite intrahepatic
tumor progression. At the time of referral to our institution,
the median preoperative Karnofsky performance index was
>80%.
Preoperative evaluation included thoracoabdominal
computed tomography (CT) scan with special regard to
portal vein anatomy, as well as 3-dimensional volumetry,
and also
18F-fluorodeoxyglucose-positron emission tomog-
raphy (FDG-PET). All data were preoperatively reviewed
by a multidisciplinary team (hepatobiliary surgeon, medical
and surgical oncologist, radiologist, and specialist in
nuclear medicine). Figure 2 shows the design of our pilot
study. The aim of the intensive preoperative imaging
conducted was to rule out disseminated intrahepatic CRLM,
which we considered as contraindication for primary
surgical exploration, and to identify extrahepatic tumor
spread. The latter was not considered as contraindication to
liver resection when curative resection seemed to be
achievable simultaneously to first-stage hepatectomy or
during prior separate surgery. Patients with unresectable
extrahepatic disease, namely with advanced local recur-
rence, disseminated pulmonary metastases, or peritoneal
carcinomatosis were not eligible for this feasibility study.
First-stage hepatectomy
First-stage hepatectomy, as the key step in our multimodal
therapy concept, was performed in all patients. After upper
midline laparotomy with right subcostal (J-shaped) exten-
sion, complete exploration of the intraperitoneal cavity was
performed. The liver was then evaluated with both
bimanual palpation and intraoperative ultrasound to identify
the intrahepatic metastatic pattern. Portal vein occlusion
was performed at the side of main tumor load. To avoid
extensive adhesions during second-stage hepatectomy,
mobilization of the liver and especially hilar dissection
were carried out most conservatively, with as minimal a
division of the falciform ligament and diaphragmatic
attachments as possible. Using a right lateral approach to
the hepatoduodenal ligament, the main portal vein was then
Table 2 First-stage hepatectomy
Number Percent
Preoperative chemotherapy for downsizing of CRLM
None 6 25
FOLFOX/FOLFIRI 12 50
FOLFOX/FOLFIRI + Bevacizumab 6 25
Effect of preoperative chemotherapy
a
Stable disease/ partial remission 8 33.3
Progressive disease 10 41.7
Surgical procedures
Right PVL 23 95.8
Left PVL 1 4.2
+ radio frequency ablation 7
b 29.2
+ non-anatomical resection 4 16.6
+ bisegmentectomy segment II/III 4 16.6
+ resection of extrahepatic disease 1 4.2
Hospitalisation (days)
c 12.3 ± 3.8 (8-28); 12
Mortality 0 0
Morbidity 3 12.6
Wound infection 1 4.2
Cardiac arrhythmia 1 4.2
Urogenitary infection 1 4.2
CTX chemotherapy, CRLM colorectal liver metastases, PVL portal
vein ligation
aRelating to intrahepatic disease; based on RECIST-criteria [14]
bIn two cases both RFA and non-anatomical resection were performed
cMean ± SD (range); Median
Table 1 Patient characteristics
Number Percent
Patients 24 100
Sex
Female 7 29.2
Male 17 70.8
Weight (kg)
a 85.9±16.8
Primary cancer
Colon 12 50
Rectum
b 12 50
Primary tumor stage
UICC I 0 0
UICC II 5 20.8
UICC III 5 20.8
UICC IV 14 58.4
Systemic therapy of primary cancer
5FU/FA + RT 50,4 Gy (neoadjuvant) 1 4.2
5-FU/FA ± Oxaliplatin (adjuvant) 8 33.4
Detection of hepatic metastases
Synchronous
c 14 58.4
Metachronous 10 41.6
UICC Union international contre le cancer, 5-FU 5-fluorouracil, FA
folinic acid, RT radiotherapy, SD standard deviation
aMean ± SD
bTNM/UICC classification (up to 16 cm above anocutaneous verge as
measured by rigide rectoscopy)
cLess than 3 months between resection of primary tumor and
diagnosis of intrahepatic metastases
Int J Colorectal Dis (2009) 24:409–418 411followed until its bifurcation into the left and right portal
veins. To facilitate redissection during second-stage hepa-
tectomy, the portal branch selected for occlusion was
transected and oversewn using nonabsorbable sutures with
the use of vascular clamps. In patients presenting with
variant portal vein anatomy, namely a bifurcation of the
main portal trunk into a right posterior and right anterior
branch with the left portal vein arising from the latter, we
modified our technique. A transection of the right posterior
branch was performed as described, followed by ligation of
the right anterior branch distal of the rise of the left portal
vein (Fig. 3). Because CRLM have been reported to grow
during liver regeneration following portal vein occlusion
[15, 16], CRLM situated near the future resection plane
were ablated by radiofrequency (RFA), suggesting that
growth rate and metastatic potential during hypertrophy
could thereby be reduced. This concerned metastases in S
IVa/b, when right trisegmentectomy was planned, and
metastases in segment V/VIII when left trisegmentectomy
was planned. CRLM in the lateral segments of the
nonligated lobe were not treated by RFA but resected. In
cases when only segments I and IV were unaffected by
CRLM, right PVL was combined with bisegmentectomy of
segment II/III.
Re-evaluation
Re-evaluation was performed routinely 6 weeks after first-
stage hepatectomy and again consisted of thoracoabdominal
CT scan with 3-dimensional volumetry and FDG-PET. All
volumetric examinations were reviewed by the same
experienced radiologist (G.S.). The second-stage procedure
was cancelled when CRLM occurred in the future remnant
liver or disseminated extrahepatic tumor spread was
diagnosed. No chemotherapy was administered between
first-stage and second-stage hepatectomy.
Fig. 2 Algorithm for treatment
of bilobular colorectal liver
metastases applied in the study.
After diagnosing bilobular
CRLM, coexistence and extent
of extrahepatic disease was
evaluated and, if necessary,
resected. During first-step hepa-
tectomy, the site of main tumor
load was identified with subse-
quent ipsilateral portal vein li-
gation or transection. CRLM in
the future remnant liver lobe
were resected completely if
present. Those metastases situ-
ated near the future resection
plane were treated by RFA to
achieve local tumor control.
Newly diagnosed extrahepatic
disease was resected simulta-
neously. When restaging after
liver hypertrophy showed no
progression of disease, second-
stage hepatectomy with major
liver resection was performed.
In case of progressive disease,
the remaining CRLM were trea-
ted by RFA, followed by che-
motherapy in palliative intention
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Depending on the extent of liver resection during the first-
stage procedure, we performed hemihepatectomy (in cases
of previous bisegmentectomy) or trisegmentectomy during
the second-stage hepatectomy. Liver parenchyma dissection
was carried out without inflow occlusion. Lymph node
dissection of the hepatoduodenal ligament was not per-
formed routinely. In patients with resectable extrahepatic
disease, this was resected simultaneously even if affecting
the lung. According to our treatment paradigm, we
cancelled the planned liver resection when new CRLM
occurred in the FRLV and treated all detectable CRLM by
RFA. The diagnosis of disseminated intra- or extrahepatic
tumor spread resulted in termination of the operation.
Postoperative liver failure was assessed according to Balzan
et al. [17].
Histopathological examination was performed according
to standard operating procedures.
Postoperative treatment
Previous immunohistochemical studies as well as analyses
of serum titers of carcinoembryonic antigen (CEA) indicate
its expression in >90% of colorectal cancer patients [18,
19]. In addition, diagnostic imaging studies with CEA-
specific antibodies have shown selective and enhanced
localization of colorectal cancer [20, 21]. Therefore, we
performed immunohistochemical staining for CEA in all
patients, and postoperative radioimmunotherapy with
131I-
labetuzumab [22, 23] was indicated on investigators’
discretion when staining intensity was assessed as moderate
or strong.
Follow-up
Patients were standardly followed up with a physical
examination, liver biochemistry, CEA, and abdominal
ultrasound every 3 months. Patients consenting to adjuvant
radioimmunotherapy underwent thoracoabdominal CT and
FDG-PET scans prior to radioimmunotherapy and after-
wards, every 6 months. No patient was lost during the
follow-up period until June 30, 2008.
Ethical considerations
All human interventions were performed in accordance
with the ethical standards laid down in the 1964 Declara-
tion of Helsinki and have been approved by the regional
ethical committee. All persons gave their informed consent
prior to their inclusion in the study.
Statistics
The Kaplan–Meier survival estimates method was used to
calculate overall survival, and significant differences were
examined using the log-rank test. A difference was
considered to be significant when the p value was less than
0.05. The analysis was performed using the statistical
software Statistica (StatSoft, Tulsa, OK, USA).
Results
First-stage hepatectomy
In23(95.8%)ofthecases, theright portalveinwasligated or
dissected; in one patient, ligation of the portal branches was
extended to segment IV. One patient underwent ligation of
the left portal vein. Additional treatment to PVL consisted of
RFA (n=7), non-anatomical resection (n=4), and biseg-
mentectomy of the left lateral segments II/III (n=4). In one
patient, preoperative CT scan had shown a suspicious,
FDG-PET-positive mass ventrocranial of the bladder, which
could be identified intraoperatively as a local lymph node
recurrence and could be completely resected. The mean
hospital stay after first-stage procedure was 12.3±3.8 days
with no mortality and a morbidity rate of 12.6% (Table 2).
Volumetric analysis
Table 3 gives a summary of the volumetric analysis. The
median number of liver metastases detected by CT scan
Fig. 3 Intraoperative situs with performed limited lateral dissection of
the hepatoduodenal ligament in a patient with variant portal vein
anatomy: the first bifurcation of the main portal vein (PV) divides the
PV into a right posterior branch and right anterior branch (both
indexed by blue vessel loops), the latter delivering the left portal vein
(white arrow). Such anatomical variation is rare occurring in less than
15% of cases [42]. Transection instead of ligation of the portal vein
branches during first-stage procedure results in technically easier
complete dissection of the hepatoduodenal ligament during second-
stage hepatectomy. It might be difficult to perform transection without
liver dissection especially for the right anterior branch in the presence
of variant portal vein splitting. Thus, in the displayed situation, we
performed transection of the right posterior branch and ligation of the
right anterior branch of the portal vein
Int J Colorectal Dis (2009) 24:409–418 413before first-stage procedure was 2.0 (range, 1–7) with a
median size of 4.0 cm (range, 0.9–11) for the largest
metastases. Median FRLV had been measured as 322 ml
with a FRLV/body weight ratio of 0.4. After PVL, the
median number of CRLM increased to 4.0 (range, 1–10),
coexistent with a slight increase in the median size of the
largest metastasis to 4.4 (range, 0.3–11) cm. While total
liver volume remained constant, FRLV increased to 419 ml
after 57.9±18 days, representing a median volume gain of
36.5% and a FRLV/body weight ratio of 0.6 before second-
stage hepatectomy.
Second-stage hepatectomy
Second-stage hepatectomy was performed in 19 (79.2%) of
24 patients (Table 4). Five patients were not eligible for
surgical reexploration due to newly diagnosed disseminated
pulmonary metastases (n=2) or progression of intrahepatic
disease with new metastases in the FRLV (n=3). These five
patients received systemic chemotherapy with palliative
intent.
Nineteen patients were suitable for re-operation, but liver
resection was cancelled in four patients due to occult
progressive disease with peritoneal carcinomatosis (n=2),
long-segment tumor infiltration of the future remnant left
hepatic vein (n=1), or tumor involvement of FRLV (n=1).
In the patient presenting with tumor infiltration of the left
hepatic vein, curative resection would have been possible
by use of extracorporal bypass and vascular reconstruction
techniques but was rejected due to an underlying cardio-
vascular disease. In both patients with intrahepatic tumor
progression, CRLM were treated by RFA during the
second-stage procedure.
In 14 of 15 cases, the planned hemihepatectomy (after
bisegmentectomy during the first-stage procedure (Fig. 4))
or trisegmentectomy could be performed. In one patient, the
resection procedure had to be changed from right triseg-
mentectomy to central liver resection of segment V/VIII
because of complete portal vein thrombosis. In two
patients, CRLM were adherent to the diaphragm, so its
partial resection was necessary to achieve tumor-free
margins. In one additional patient, a pulmonary metastasis
located in the right lower lobe was simultaneously resected
via a transdiaphragmatic approach.
Re-operation was necessary in one case 6 days after
curative second-stage hepatectomy due to biliary leakage.
However, the patient died 28 days after right trisegmentec-
tomy due to liver failure caused by left hepatic artery
thrombosis. Mortality and morbidity rates of the second-
stage procedure were 5.3% and 57.9%, respectively. Based
on intensive histopathological examinations, curative re-
section could be achieved in 14 of 15 (93.3%) performed
Table 3 Volumetric data of the liver parenchyma
Mean ± SD Range Median
No. of liver metastases before
PVL (n)
3.1±2.3 1–72
Size of largest liver metastasis
before PVL (cm)
4.3±2.9 0.9–11 4
TLV before PVL (ml) 1752.3±413.5 1613.5
FRLV before PVL (ml) 350.5±111 322
FRLV/body weight ratio before
PVL
0.42±0.11 0.4
No. of liver metastases after
hypertrophy (n)
4.2±3.3 1–10 4
Size of largest liver metastasis
after hypertrophy (cm)
4.8±2.9 0.3–11 4.4
TLV after hypertrophy (ml) 1712.4±397.8 1610
FRLV after hypertrophy (ml) 475±171.4 419
time between PVL and re-
evaluation (days)
57.9±18 55
ΔFRLV (ml) 123.2±106.7 114
ΔFRLV (%) 35.7±29.3 36.5
TLV/FRLV ratio 28±6.4 29
FRLV/body weight ratio 0.58±0.23 0.6
PVL portal vein ligation, TLV total liver volume, FRLV future remnant
liver volume
Table 4 Second-stage hepatectomy
Number Percent
a
Second-stage hepatectomy performed 19 79.2
b
Liver resection 15 62.5
b
Right trisegmentectomy (SIV-VIII) 13 68.4
Right hemihepatectomy (SV-VIII)
c 1 5.3
Central liver resection (S V/VIII) 1 5.3
Surgical exploration, RFA 2 10.5
Surgical exploration, but no specific therapy 2 10.5
Multivisceral resection
Diaphragm/ lung 3 15.8
Curative resection rate
d 14 93.3
CEA expression of tumor cells strong or
moderate
d
15 100
Mortality 1 5.3
Morbidity
f 11 57.9
Liver insufficiency
e 3 15.8
Biliary leakage 4 21.1
Wound healing 1 5.3
Cardiopulmonal 4 21.1
Reoperation 1 5.3
aPercentage in correlation to number of patients re-explored
bPercentage in correlation to number of patients in the study
cAfter bisegmentectomy S II/III at first-stage hepatectomy
dOnly patients with liver resection during second-stage hepatectomy
eDefined by prothrombin time <50% and serum bilirubin >50 μmol/
l on post-op day 5 [17]
fIn patients with multiple complications, each is counted separately
414 Int J Colorectal Dis (2009) 24:409–418liver resections. In all cases, immunohistochemical exam-
ination revealed a moderate (n= 1 )o rs t r o n g( n=14)
expression of CEA on the surface of tumor cells.
Follow-up
Follow-up was documented for the 13 patients with
curative resection. Four patients received no adjuvant
therapy following hepatic resection, while eight patients
were enrolled in an adjuvant radioimmunotherapy protocol.
Two months after R0-resection, one patient died of
pulmonary embolism. During a median follow-up period
of 17 months, ten patients developed recurrent disease
(Table 5) that, at the time of diagnosis, was multifocal in
one, confined to the liver in one, and limited to the lung in
six patients. Two additional patients presented with bone
metastases after a disease-free survival of 5 and 6 months,
respectively. Only one patient with a solitary pulmonary
metastasis was suitable for surgical therapy and has been
free of disease for 22 months, while in all other cases of
tumor recurrence, chemotherapy or radiochemotherapy
was applied. Three patients with recurrent disease died
14, 17, and 27 months, respectively, after second-stage
procedure because of tumor progression. Two other
patients with recurrent disease showed no progression
under chemotherapy.
Discussion
This pilot study describes our experience with two-stage
hepatectomy using portal vein ligation in patients with
bilobular CRLM. These patients are associated with poor
prognosis, and only if curative resection can be achieved, 5-
year survival rates may reach 20% [3]. Therefore, every
attempt should be made to convert initially unresectable to
resectable patients which can be achieved by two-stage
hepatectomy.
To induce hypertrophy of the FRLV, we favored surgical
PVL instead of interventional PVE, although it has been
reported by Broering et al. [24] to result in a significantly
lower increase in liver volume. However, this conclusion
should be restrained because the authors also showed a
Table 5 Follow-up
Patient No. Time to recurrence
a Recurrence site Treatment Outcome at last observation OS
b Status
1 4 Hepar, pulmo CTX PD 14 DOT
2P 1 Pulmo, osseous
c CTX PD 27 DOT
3 2 Pulmo CTX PD 17 DOT
4P 6 Pulmo CTX PD 18 A
5 6 Osseous RTX PD 21 A
6 5 Osseous RTX PD 10 A
7 2 Pulmo CTX PD 7 A
8 3 Hepar, pulmo
c CTX SD 17 A
9P 1 Pulmo CTX SD 17 A
10 –– – NED 2 DOC
11P –– – NED 21 A
12 –– – NED 12 A
13 7 Pulmo Surgery NED 29 A
CTX chemotherapy, RTX radiochemotherapy, A alive, DOT dead of tumor, DOC dead of other cause (pulmonary embolism), P progression under
chemotherapy before liver resection, PD progressive disease, SD stable disease, NED no evidence of disease
aTime between second-stage hepatectomy and diagnosis of tumor recurrence (month), last observation 2008, 6, 30
bTime between second-stage hepatectomy and last observation
cSecond side of recurrence under chemotherapy
Fig. 4 CT scan of the upper abdomen in portalvenous phase
demonstrating enormous hypertrophy of segment I and IV after
bisegmentectomy S II/III during first-stage hepatectomy, followed by
standard right hemihepatectomy during second-stage hepatectomy. CT
scan was performed 18 months after second-stage hepatectomy. PV
portal vein, VCI inferior vena cava
Int J Colorectal Dis (2009) 24:409–418 415significantly higher volume gain when portal vein branches
to segment IV were occluded simultaneously, and this was
done significantly more often in the PVE group. Further-
more, a recent publication by Aussilhou et al. [25]
concluded that PVE and PVL result in comparable liver
hypertrophy.
Compared to preoperative staging data, the surgical
approach with PVL enhances sensitivity and specificity in
the detection of CRLM using intraoperative ultrasound [26,
27]. It also allows combined PVL- and CRLM-directed
therapy, even simultaneously with primary tumor resection
without increasing morbidity or mortality rates [28, 29].
Although not as part of surgery for primary tumor, we
performed liver resection up to bisegmentectomy and
radiofrequency ablation together with PVL in eight and
seven patients, respectively.
A number of studies have compared the efficacy of liver
resection and RFA in the treatment of CRLM. They have
demonstrated clearly that overall survival rates are higher,
and local recurrence rates are lower in patients treated with
resection [1, 30, 31]. Moreover, in cases where CRLM
could not be resected completely, resection and RFA
together did not significantly increase survival compared
with RFA alone. Facing these results and remembering the
categorical high risk of recurrence in patients with bilobular
CRLM, RFA proves inappropriate for the treatment of
CRLM in the nonligated hemi-liver.
Accordingly, the present series describes an aggressive
two-stage hepatectomy concept with combination of PVL
and complete surgical clearance of the nonligated hemiliver.
Other authors [6] discussed that PVL combined with liver
resection during first-stage hepatectomy may induce post-
operative liver failure. In contrast, in our experience with
24 cases, no liver failure due to insufficient amount of liver
volume occurred after the first-stage procedure, even
though we performed bisegmentectomy of segments II/III
in four patients (Table 2). In all patients, we observed a
sufficient increase in FRLV using PVL with a mean interval
of 57.9±18 days, and cancellation of second-stage hepa-
tectomy was in no case based on insufficient hypertrophy.
Addressing oncological strategies, it has to be observed
that there is still some controversy about whether chemother-
apy, given between the two surgical procedures, is beneficial
with regard to the curative resection rate. Severe sinusoidal
injury has been observed in liver specimens after chemother-
apy prior to liver resection [32–34], with some authors
reporting an increased postoperative morbidity [33]—or
even mortality rate [34]. Otherwise, intensive systemic
chemotherapy with infusional 5-fluorouracil, folinic acid,
and oxaliplatin or irinotecan have demonstrated response
rates of up to 56% in primarily unresectable CRLM [35],
resulting in curative resection rates of 12.5% [9], of which a
high percentage will ask for two-stage procedures. Tumor
progression can be observed during liver hypertrophy not
only in the nonligated [15] but also in the ligated lobe [16],
which our data also demonstrate with regard to both number
and size of CRLM (Table 2). Thus, there is a need for
antitumor therapy between first- and second-stage hepatec-
tomy, especially to control micrometastatic disease.
Besides systemic treatment, application of local chemo-
therapy has been studied in this context. Selzner et al. [36]
treated 11 patients with PVL and intrahepatic arterial
chemotherapy based on the antimetabolite, floxuridine.
Although FRLV increased significantly 3 months after
PVL, only six patients showed a partial response [14]t o
local chemotherapy, with an overall curative resection rate
of only 36%. In a recently published study, Lygidakis et al.
[28] also combined the surgical approach with three cycles
of intra-arterial chemotherapy in 32 patients with synchro-
nous bilobular CRLM. Two days after first-stage procedure
including PVL, they started a complex transarterial chemo-
therapy schedule including oxaliplatin, irinotecan, mitomy-
cin C, 5-fluorouracil, and calcium folinate, as well as the
monoclonal antibody, bevacizumab. The chemotherapy was
administered over 5 days with the next cycle following after
25 days. Major liver resection was performed 3 weeks after
completing the third cycle of chemotherapy. Curative
resection was possible in all patients, with a 2-year survival
rate of 80%. Considering our number of five patients,
though, that did not undergo second-stage hepatectomy
based on intrahepatic (n=3) or pulmonary (n=2) progres-
sion, plus those four patients without major liver resection
during second-stage procedure, a need for further studies on
the appropriate management strategy in these patients
becomes clear.
Curative resection could be achieved in 14 out of 19
re-explored patients (73.7%) even though we included
patients with progression under chemotherapy and even
patients with intrahepatic recurrence. In one of our
patients, complete portal vein thrombosis required a
switch in the operative resection strategy. Note that neither
tumor progression, prothrombotic disorder, or infection
was diagnosed in this case [37]. Instead of right triseg-
mentectomy, we performed central liver resection with
curative intent. Although technically possible, we did not
intend central liver resection initially because it is more
complex, results in a wide resection plane which increases
the risk for biliary fistula, and is associated with a longer
parenchymal transection time as well as elevated intra-
operative blood loss [38].
Patients with bilobular CRLM which are classified as
mT4 according to Gayowski et al. [3] experience poor
prognosis when compared to those having unilobular
involvement. During early follow-up, we identified lung
metastases in four patients already 1 (n=2) and 2 (n=2)
months after curative liver resection (Table 5), respectively.
416 Int J Colorectal Dis (2009) 24:409–418They have to be classified as occult metastatic disease at the
time of restaging prior to second-stage hepatectomy. Thus,
prolonging the interval between the two surgical procedures
to 3 months seems to be reasonable because it would allow
occult diseases to be disclosed. However, even though our
follow-up period was short, only in two patients was the
liver the first site of tumor recurrence, whereas other
authors reported an intrahepatic recurrence rate of 48–
75% during a comparable time frame [6, 39]. The low
intrahepatic recurrence rate may result from our aggressive
approach of resecting all CRLM in the FRLV.
Histopathological examination of the obtained liver
specimens revealed moderate or even strong expression of
carcinoembryonic antigen on the surface of tumor cells in
all patients. As a result, postoperative radioimmunotherapy
with
131I-labetuzumab, as described previously [22, 23],
has been offered to all patients resected curatively.
There is interdisciplinary consensus that only unresect-
able extrahepatic disease, unfit condition, and liver involve-
ment of >6 segments excludes patients from liver resection
for CRLM [40]. Therefore, the aim of the present study was
to evaluate the outcome of consecutive patients fulfilling
our inclusion criteria without preselecting them based on
previous therapies and their response profiles. The under-
lying rationale of this study design is the definition of
resectability as crucial end point in treatment concepts with
curative intent [40]. However, as almost 75% of patients
relapse after liver resection [41] within 2 years postsalvage
resection of liver metastases, the observed and expected
recurrence rate in our study population with already poor
prognosis again argues for aggressive multimodal treatment
prior to and especially postsalvage liver resection as well as
for the establishment of reliable predictive clinical and
molecular parameters that will allow patient stratification.
In conclusion, two-stage hepatectomy with portal vein
ligation and complete surgical clearance of FRLV is a
reasonable strategy in patients with bilobular, initially
unresectable CRLM. The curative resection rate results in
73.7% of the re-explored cases. Further clinical trials are
needed to evaluate whether antitumor therapy during liver
hypertrophy may positively affect the curative resection rate
by limiting the observed tumor progression after portal vein
occlusion. Although not mandatory for volume gain, a
second-stage procedure should be delayed by 3–6 months
in cases of suspicious lesions found during restaging, in
order to reduce unnecessary examinations in patients with
unresectable and progressive disease. The described
advances in the treatment of patients with bilobular
CRLM have radically redefined what constituted an
unresectable pattern of CRLM. Any patient with CRLM
should be reviewed by a multidisciplinary team of experts,
and resectability should be assessed by an experienced
hepatobiliary surgeon before a decision on management is
made. The treatment of tumor recurrence especially
extrahepatic remains a future challenge.
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